Growing at an annualized rate of 12%, the HPAPI and cytotoxic drugs contract manufacturing market
Roots Analysis has done a detailedstudy on “HPAPIand Cytotoxic Drugs Manufacturing (3rd Edition)2020-2030.” covering keyaspects of the industry’s evolution and identifying potential future growthopportunities.
To order this 300+page report, which features 75+ figures and 150+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/hpapi-and-cytotoxic-drugs-manufacturing/299.html
Key Market Insights
§ Close to 120companies across the globe claim to possess the requiredexpertise and infrastructure to offer contract manufacturing services forHPAPIs and cytotoxic drugs
§ The market is fragmented,featuring the presence of both established players and new entrants based indifferent geographies that claim to be capable of manufacturing highly potentproducts, at varying scales of operation
§ In order to acquirecompetencies across the supply chain and cater to evolving needs of sponsors,companies offering services across different scales of operation haveestablished presence in various geographical regions
§ In recent years, asteady increase in partnership activity has been observed in this domain; avariety of deals have been inked related to highly potent drug products
§ In order to enhancethe core competencies in this domain, CMOs are actively investing in upgradingexisting infrastructure and expanding their respective manufacturing capacities
§ Most of theinstalled, global HPAPI and cytotoxic drug manufacturing capacity belongs toestablished CMOs, accounting for close to 75% of the available capacity acrossvarious geographies
§ Case-in-point: ADCs represent a significantgrowth opportunity; over 30 CMOs currently extend their services to manufactureone or multiple components of an ADC molecule
§ We expect highly potent drug developers to continue to outsource theirmanufacturing operations in the mid to long term, causing service-basedrevenues to grow at an annualized rate of more than 10%
§ In the long-term, the projected opportunity for the contractmanufacturing of HPAPIs and cytotoxic drugs is likely to be well distributedacross various dosage forms, nature of molecules and sizes of contract serviceproviders
For more information, please visit https://www.rootsanalysis.com/reports/view_document/hpapi-and-cytotoxic-drugs-manufacturing/299.html
Table of Contents
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Highly PotentActive Pharmaceutical Ingredients (HPAPIs)
3.2.1. Classification based on Potencyof Pharmacological Ingredients
3.2.2. Types of HPAPIs
3.2.3. Challenges Associated withHandling HPAPIs
3.2.4. Considerations for HandlingHPAPIs
3.2.5. Contract Manufacturing of HPAPIsand Cytotoxic Drugs
3.2.5.1. Selection of a Suitable CMO Partner for HPAPI Manufacturing
3.2.6. Regulatory Considerations forHPAPI Manufacturing
3.2.7. Concluding Remarks
4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. HPAPI and Cytotoxic DrugsContract Manufacturers: Overall Market Landscape
4.2.1. Analysis by Year ofEstablishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Scale of Operation
4.2.4. Analysis by Type of Service(s)Offered
4.2.5. Analysis by Type of Product
4.2.6. Analysis by Type ofPharmacological Molecule
4.2.7. Analysis by Location ofHeadquarters
4.2.8. Analysis by Location ofManufacturing Facilities
4.2.9. Analysis by Facility Size
4.2.10. Analysis by Type of Highly PotentFinished Dosage Forms (FDFs)
4.2.11. Analysis by Type of PrimaryPackaging
5. COMPANYCOMPETITIVE ANALYSIS
5.1. ChapterOverview
5.2. Methodology
5.3. Assumptionsand Key Parameters
5.4. CompanyCompetitiveness Analysis: HPAPI and Cytotoxic Drugs Contract Manufacturersbased in North America
5.5. CompanyCompetitiveness Analysis: HPAPI and Cytotoxic Drugs Contract Manufacturersbased in Europe
5.6. CompanyCompetitiveness Analysis: HPAPI and Cytotoxic Drugs Contract Manufacturersbased in Asia Pacific and Rest of the World
6. HPAPIAND CYTOTOXIC DRUGS CONTRACT MANUFACTURERS BASED IN NORTH AMERICA: COMPANYPROFILES
6.1. ChapterOverview
6.2. AbbVieContract Manufacturing
6.2.1. CompanyOverview
6.2.1.1. HPAPI andCytotoxic Drugs Manufacturing Service Offerings
6.2.1.2. ManufacturingFacilities
6.2.1.3. RecentDevelopments
6.2.1.4. FutureOutlook
6.3. Catalent
6.3.1. CompanyOverview
6.3.1.1. HPAPI andCytotoxic Drugs Manufacturing Service Offerings
6.3.1.2. ManufacturingFacilities
6.3.1.3. RecentDevelopments
6.3.1.4. FutureOutlook
6.4. PfizerCentreOne
6.4.1. CompanyOverview
6.4.1.1. HPAPIand Cytotoxic Drugs Manufacturing Service Offerings
6.4.1.2. ManufacturingFacilities
6.4.1.3. RecentDevelopments
6.4.1.4. FutureOutlook
6.5. PiramalPharma Solutions
6.5.1. CompanyOverview
6.5.1.1. HPAPIand Cytotoxic Drugs Manufacturing Service Offerings
6.5.1.2. ManufacturingFacilities
6.5.1.3. RecentDevelopments
6.5.1.4. FutureOutlook
6.6. SAFC(a business division of Sigma-Aldrich)
6.6.1. CompanyOverview
6.6.1.1. HPAPIand Cytotoxic Drugs Manufacturing Service Offerings
6.6.1.2. ManufacturingFacilities
6.6.1.3. RecentDevelopments
6.6.1.4. FutureOutlook
7. HPAPIAND CYTOTOXIC DRUGS CONTRACT MANUFACTURERS BASED IN EUROPE: COMPANY PROFILES
7.1. ChapterOverview
7.2. CarbogenAmics
7.2.1. CompanyOverview
7.2.1.1. HPAPIand Cytotoxic Drugs Manufacturing Service Offerings
7.2.1.2. ManufacturingFacilities
7.2.1.3. RecentDevelopments
7.2.1.4. FutureOutlook
7.3. Evonik
7.3.1. CompanyOverview
7.3.1.1. HPAPIand Cytotoxic Drugs Manufacturing Service Offerings
7.3.1.2. ManufacturingFacilities
7.3.1.3. RecentDevelopments
7.3.1.4. FutureOutlook
7.4. Lonza
7.4.1. CompanyOverview
7.4.1.1. HPAPIand Cytotoxic Drugs Manufacturing Service Offerings
7.4.1.2. ManufacturingFacilities
7.4.1.3. RecentDevelopments
7.4.1.4. FutureOutlook
7.5. Siegfried
7.5.1. CompanyOverview
7.5.1.1. HPAPIand Cytotoxic Drugs Manufacturing Service Offerings
7.5.1.2. ManufacturingFacilities
7.5.1.3. RecentDevelopments
7.5.1.4. FutureOutlook
7.6. TevaAPI
7.6.1. CompanyOverview
7.6.1.1. HPAPIand Cytotoxic Drugs Manufacturing Service Offerings
7.6.1.2. ManufacturingFacilities
7.6.1.3. RecentDevelopments
7.6.1.4. FutureOutlook
8. HPAPIAND CYTOTOXIC DRUGS CONTRACT MANUFACTURERS BASED IN ASIA PACIFIC: COMPANYPROFILES
8.1. ChapterOverview
8.2. FormosaLaboratories
8.2.1. CompanyOverview
8.2.1.1. HPAPIand Cytotoxic Drugs Manufacturing Service Offerings
8.2.1.2. ManufacturingFacilities
8.2.1.3. RecentDevelopments
8.2.1.4. FutureOutlook
8.3. IntasPharmaceuticals
8.3.1. CompanyOverview
8.3.1.1. HPAPIand Cytotoxic Drugs Manufacturing Service Offerings
8.3.1.2. ManufacturingFacilities
8.3.1.3. FutureOutlook
8.4. MabPlex
8.4.1. CompanyOverview
8.4.1.1. HPAPIand Cytotoxic Drugs Manufacturing Service Offerings
8.4.1.2. ManufacturingFacilities
8.4.1.3. FutureOutlook
8.5. ScinoPharm
8.5.1. CompanyOverview
8.5.1.1. HPAPIsand Cytotoxic Drugs Manufacturing Service Offerings
8.5.1.2. ManufacturingFacilities
8.5.1.3. FutureOutlook
8.6. STAPharmaceutical (a WuXi AppTec company)
8.6.1. CompanyOverview
8.6.1.1. HPAPIand Cytotoxic Drugs Manufacturing Service Offerings
8.6.1.2. ManufacturingFacilities
8.6.1.3. RecentDevelopments
8.6.1.4. FutureOutlook
9. PARTNERSHIPSAND COLLABORATIONS
9.1. ChapterOverview
9.2. PartnershipModels
9.3. HPAPIand Cytotoxic Drugs Contract Manufacturers: List of Partnerships andCollaborations
9.3.1. Analysisby Year of Partnership
9.3.2. Analysisby Type of Partnership
9.3.3. Analysisby Type of Product
9.3.4. Analysisby Scale of Operation
9.3.5. Analysisby Company Size
9.3.6. Analysisof Acquisitions by Amount Invested
9.3.7. MostActive Players: Analysis by Number of Partnerships
9.3.8. GeographicalAnalysis
9.3.8.1. Continent-wise Distribution
9.3.8.2. Country-wise Distribution
10. RECENTEXPANSIONS
10.1. Chapter Overview
10.2. HPAPI andCytotoxic Drugs Contract Manufacturers: Recent Expansions
10.2.1. Analysis byYear of Expansion
10.2.2. Analysis byType of Expansion
10.2.3. Analysis byScale of Operation and Type of Expansion
10.2.4. Analysis byType of Product and Type of Expansion
10.2.5. Analysisby Expanded Facility Area
10.2.6. Analysisby Amount Invested
10.2.7. Analysisby Company Headquarters and Company Size
10.2.8. Analysisby Location of Facility and Type of Expansion
10.2.9. MostActive Players: Analysis by Number of Expansions
10.2.10. Geographical Analysis
10.2.10.1. Continent-wise Distribution
10.2.10.2. Country-wise Distribution
11. CAPACITYANALYSIS
11.1. ChapterOverview
11.2. KeyAssumptions and Methodology
11.3. HPAPIand Cytotoxic Drugs Contract Manufacturers: Global, Installed Capacity
11.3.1. Analysisby Company Size
11.3.2. Analysisby Scale of Operation
11.3.3. Analysisby Location of Manufacturing Facility
11.4. ConcludingRemarks
12. MAKEVERSUS BUY DECISION MAKING FRAMEWORK
12.1. ChapterOverview
12.2. HPAPIand Cytotoxic Drugs Contract Manufacturing: Make versus Buy Decision Making
13. MARKETSIZING AND OPPORTUNITY ANALYSIS
13.1. ChapterOverview
13.2. ForecastMethodology and Key Assumptions
13.3. OverallHPAPI and Cytotoxic Drugs Contract Manufacturing Market, 2020-2030
13.4. HPAPI and Cytotoxic Drugs ContractManufacturing Market, 2020-2030: Distribution by Type of Product
13.5. HPAPIand Cytotoxic Drugs Contract Manufacturing Market, 2020-2030: Distribution byCompany Size
13.6. HPAPIand Cytotoxic Drugs Contract Manufacturing Market, 2020-2030: Distribution byScale of Operation
13.7. HPAPI and Cytotoxic Drugs Contract Manufacturing Market,2020-2030: Distribution by Type of Pharmacological Molecule
13.8. HPAPIand Cytotoxic Drugs Contract Manufacturing Market, 2020-2030: Distribution byType of Highly Potent Finished Dosage Forms
13.9. HPAPIand Cytotoxic Drugs Contract Manufacturing Market, 2020-2030: Distributionacross Key Geographical Regions
13.9.1. HPAPIand Cytotoxic Drugs Contract Manufacturing Market in North America, 2020-2030
13.9.1.1. HPAPI and Cytotoxic Drugs ContractManufacturing Market in the US, 2020-2030
13.9.1.2. HPAPI and Cytotoxic Drugs ContractManufacturing Market in Canada, 2020-2030
13.9.1.3. HPAPI and Cytotoxic Drugs ContractManufacturing Market in Mexico, 2020-2030
13.9.2. HPAPIand Cytotoxic Drugs Contract Manufacturing Market in Europe, 2020-2030
13.9.2.1. HPAPI and Cytotoxic Drugs ContractManufacturing Market in the UK, 2020-2030
13.9.2.2. HPAPI and Cytotoxic Drugs ContractManufacturing Market in Italy, 2020-2030
13.9.2.3. HPAPI and Cytotoxic Drugs ContractManufacturing Market in Germany, 2020-2030
13.9.2.4. HPAPI and Cytotoxic Drugs ContractManufacturing Market in France, 2020-2030
13.8.2.5. HPAPI and Cytotoxic Drugs ContractManufacturing Market in Spain, 2020-2030
13.9.2.6. HPAPI and Cytotoxic Drugs ContractManufacturing Market in Rest of Europe, 2020-2030
13.9.3. HPAPIand Cytotoxic Drugs Contract Manufacturing Market in Asia Pacific, 2020-2030(USD Billion)
13.9.3.1. HPAPI and Cytotoxic Drugs ContractManufacturing Market in China, 2020-2030
13.9.3.2. HPAPI and Cytotoxic Drugs ContractManufacturing Market in India, 2020-2030
13.9.3.3. HPAPIand Cytotoxic Drugs Contract Manufacturing Market in Rest of Asia Pacific,2020-2030
13.9.4. HPAPIand Cytotoxic Drugs Contract Manufacturing Market in the Rest of the World,2020-2030
14. SWOTANALYSIS
14.1. ChapterOverview
14.2. Strengths
14.3. Weaknesses
14.4. Opportunities
14.5. Threats
14.6. ConcludingRemarks
15. CASE-IN-POINT:CONTRACT MANUFACTURING OF ANTIBODY DRUG CONJUGATES
15.1. ChapterOverview
15.2. KeyComponents of ADCs
15.2.1. Antibody
15.2.2. Cytotoxin
15.2.3. Linker
15.3. Overviewof ADC Manufacturing
15.3.1. KeyProcess Steps
15.3.2. ChallengesAssociated with ADC Manufacturing
15.3.3. GrowingTrend of Outsourcing in ADC Manufacturing
15.4. ChallengesAssociated with Supply Chain and Method Transfer
15.5. GrowingDemand for One-Stop-Shops and Integrated Service Providers
15.6. KeyConsiderations for Selecting a CMO Partner
15.7. ADCContract Manufacturers: Overall Market Landscape
15.7.1. Analysisby Location of Headquarters
15.7.2. Analysisby Year of Establishment
15.7.3. Analysisby Company Size
15.7.4. Analysisby Service(s) Offered
15.7.5. Analysisby Location of Headquarters
15.7.5. Analysisby Location of Manufacturing Facility
15.7.6. Analysisby Scale of Operation
16. CONCLUDINGREMARKS
17. EXECUTIVEINSIGHTS
17.1. ChapterOverview
17.2. BSPPharmaceuticals
17.2.1. CompanySnapshot
17.2.2. InterviewTranscript: Antonella Mancuso and Maria Elena Guadagno, Vice President andChief Operating Officer and Business Director
17.3. Catalent
17.3.1. CompanySnapshot
17.3.2. InterviewTranscript: Stacy McDonald and Jennifer L. Mitcham, Group Product Manager andDirector-Business Development
17.4. CordenPharma
17.4.1. CompanySnapshot
17.4.2. InterviewTranscript: Roberto Margarita, Business Development Director
17.5. Helsinn
17.5.1. CompanySnapshot
17.5.2. InterviewTranscript: Allison Vavala, Senior Manager, Business Development
17.6. Idifarma
17.6.1. CompanySnapshot
17.6.2. InterviewTranscript: Javier E. Aznárez Araiz, Business Development
17.7. PiramalHealthcare
17.7.1. CompanySnapshot
17.7.2. InterviewTranscript: Dr. Mark Wright, Site Head, Grangemouth
17.8 ProJectPharmaceutics
17.8.1. CompanySnapshot
17.8.2. InterviewTranscript: Klaus Hellerbrand, Managing Director
17.9. AlphoraResearch
17.9.1. CompanySnapshot
17.9.2. InterviewTranscript: Kevin Rosenthal, Business Head, Formulations and Finished Products
18. APPENDIX1: TABULATED DATA
19. APPENDIX2: LIST OF COMPANIES AND ORGANIZATIONS
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
